• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Adrian Wiestner, MD, PhD, Discusses the Clinical and Economic Outcomes Associated With the Use of Targeted Kinase Inhibitors in CLL

Article

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL).

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL). He notes that, currently, there may not be enough information to develop a comprehensive understanding of the economic implications, but offers that, perhaps looking at chronic myelogenous leukemia (CML) will provide some important relative insight.

This video was taken on Monday, December 10, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Dr Bonnie Qin
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.